Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
DOBMEIER ERIC | President, CEO | Apr 24 | Option Exercise | 0.42 | 25,000 | 10,500 | 326,138 | Apr 26 05:19 PM | DOBMEIER ERIC | President, CEO | Apr 24 | Sale | 21.58 | 23,800 | 513,528 | 302,338 | Apr 26 05:19 PM | Jerel Davis | Director | Apr 17 | Sale | 20.75 | 295,808 | 6,138,223 | 443,713 | Apr 19 05:58 PM | Krishnan Mahesh | Director | Apr 04 | Sale | 23.01 | 924 | 21,261 | 1,275 | Apr 04 09:14 PM | King Andrew James | Chief Scientific Officer | Apr 03 | Option Exercise | 0.35 | 2,500 | 875 | 21,992 | Apr 05 04:43 PM | King Andrew James | Chief Scientific Officer | Apr 03 | Sale | 23.34 | 5,000 | 116,718 | 16,992 | Apr 05 04:43 PM | Jerel Davis | Director | Mar 01 | Sale | 22.75 | 400,000 | 9,100,000 | 210,996 | Mar 03 04:13 PM | DOBMEIER ERIC | President, CEO | Feb 10 | Sale | 23.75 | 8,097 | 192,292 | 301,138 | Feb 15 04:40 PM | Frohlich Tom | Chief Operating Officer | Feb 10 | Sale | 23.75 | 3,700 | 87,869 | 150,777 | Feb 15 04:40 PM | King Andrew James | Chief Scientific Officer | Feb 10 | Sale | 23.75 | 2,392 | 56,806 | 19,492 | Feb 15 04:39 PM | BJERKHOLT ERIC | Chief Financial Officer | Feb 10 | Sale | 23.75 | 857 | 20,352 | 38,867 | Feb 15 04:41 PM | DOBMEIER ERIC | President, CEO | Jan 31 | Sale | 24.68 | 7,688 | 189,757 | 288,987 | Feb 01 08:32 PM | Frohlich Tom | Chief Operating Officer | Jan 31 | Sale | 24.68 | 4,566 | 112,700 | 147,674 | Feb 02 06:15 PM | King Andrew James | Chief Scientific Officer | Jan 31 | Sale | 24.68 | 3,244 | 80,069 | 15,081 | Feb 02 06:13 PM | BJERKHOLT ERIC | Chief Financial Officer | Jan 31 | Sale | 24.68 | 2,891 | 71,357 | 37,289 | Feb 02 06:14 PM | DOBMEIER ERIC | President, CEO | Jan 30 | Option Exercise | 0.42 | 25,000 | 10,500 | 296,676 | Feb 01 08:32 PM | DOBMEIER ERIC | President, CEO | Jan 30 | Sale | 24.54 | 25,000 | 613,612 | 271,676 | Feb 01 08:32 PM | King Andrew James | Chief Scientific Officer | Jan 03 | Option Exercise | 0.35 | 7,500 | 2,625 | 19,992 | Jan 04 07:44 PM | King Andrew James | Chief Scientific Officer | Jan 03 | Sale | 25.82 | 10,000 | 258,183 | 9,992 | Jan 04 07:44 PM | DOBMEIER ERIC | President, CEO | Dec 14 | Option Exercise | 0.35 | 30,000 | 10,500 | 271,676 | Dec 15 04:27 PM | Frohlich Tom | Chief Operating Officer | Dec 13 | Option Exercise | 0.42 | 10,000 | 4,200 | 153,907 | Dec 15 04:28 PM | Frohlich Tom | Chief Operating Officer | Dec 13 | Sale | 25.00 | 10,000 | 250,005 | 143,907 | Dec 15 04:28 PM | DOBMEIER ERIC | President, CEO | Dec 01 | Option Exercise | 0.42 | 60,000 | 25,200 | 271,676 | Dec 02 04:26 PM | DOBMEIER ERIC | President, CEO | Dec 01 | Sale | 22.31 | 30,000 | 669,351 | 241,676 | Dec 02 04:26 PM | BJERKHOLT ERIC | Chief Financial Officer | Dec 01 | Sale | 22.29 | 5,770 | 128,602 | 32,847 | Dec 02 04:25 PM | Frohlich Tom | Chief Operating Officer | Nov 07 | Option Exercise | 0.42 | 10,000 | 4,200 | 153,907 | Nov 09 04:21 PM | Frohlich Tom | Chief Operating Officer | Nov 07 | Sale | 22.16 | 10,000 | 221,642 | 143,907 | Nov 09 04:21 PM | Frohlich Tom | Chief Operating Officer | Oct 06 | Sale | 19.69 | 7,360 | 144,933 | 143,907 | Oct 11 04:33 PM | King Andrew James | Chief Scientific Officer | Oct 06 | Sale | 19.69 | 3,557 | 70,044 | 12,492 | Oct 11 04:32 PM | Thomas Dolca | Director | Sep 02 | Buy | 21.22 | 10,000 | 212,194 | 10,000 | Sep 06 04:35 PM | King Andrew James | Chief Scientific Officer | Aug 04 | Option Exercise | 0.35 | 5,000 | 1,750 | 10,897 | Aug 05 05:09 PM | King Andrew James | Chief Scientific Officer | Aug 04 | Sale | 20.00 | 5,000 | 100,000 | 5,897 | Aug 05 05:09 PM | King Andrew James | Chief Scientific Officer | Jul 11 | Option Exercise | 0.35 | 5,000 | 1,750 | 10,897 | Jul 13 04:11 PM | King Andrew James | Chief Scientific Officer | Jul 11 | Sale | 18.09 | 5,000 | 90,468 | 5,897 | Jul 13 04:11 PM |
|